Amneal Pharmaceuticals, Inc. announced that it has received FDA approval for a generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The company is planning to commercialize its Rivastigmine Transdermal System shortly. According to IQVIA, U.S market annual sales for the 12 months ended November 2018 for Rivastigmine Transdermal System is estimated to be approximately $225 million.